Depression continues to grapple a large proportion of the population. Given the side effects associated with the long-term use of conventional antidepressants, there is a need for novel rapid acting therapeutics with minimal side effects. Researchers have previously demonstrated antidepressant-like effects of delta opioid receptor agonists in rodents. In their latest study, they uncover the molecular and cellular mechanism underlying its action that can advance its therapeutic development.